Onconova Therapeutics, Inc. filed a letter providing an update on their clinical development program for rigosertib, including positive results from a Phase 2 trial in higher-risk myelodysplastic syndromes (HR-MDS) patients and plans for a Phase 3 tr
AI Assistant
TRAWS PHARMA INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.